Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

5th International Thymic Malignancy Interest Group Annual Meeting

5th International Thymic Malignancy Interest Group Annual Meeting ITMIG 2014 Abstracts Journal of Thoracic Oncology • Volume 9, Number 10, Supplement 4, September 2014 clinical data. All TETs expressed PD-L1 in our TET TMA. Though benign thymus also stained for PD-L1, TETs stained more intensely ORAL ABSTRACT SESSION 1: for PD-L1. PD-L1 expression is a potential biomarker for benefit to BIOLOGY OF THYMIC MALIGNANCIES anti-PD1/PD-L1 therapies. Our findings lend support to a clinical September 5, 2014 11:45-12:45 trial targeting PD1/PD-L1 in this rare tumor type. Disclosure: No significant relationships. ORAL ABSTRACT SESSION 1: BIOLOGY OF THYMIC MALIGNANCIES Keyword: PD-L1, PD-1, thymoma September 5, 2014 11:45-12:45 O1.01 ORAL ABSTRACT SESSION 1: BIOLOGY OF THYMIC MALIGNANCIES September 5, 2014 11:45-12:45 PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EX- PRESSION IN A THYMOMA TISSUE MICROARRAY (TMA) O1.02 1 2 Sukhmani Kaur Padda , Jonathan W. Riess , Erich Jurgen 3 4 1 1 QUANTITATIVE MEASUREMENT OF PROGRAMMED DEATH Schwartz , Lu Tian , Holbrook Edwin Kohrt , Joel W. Neal , Robert 3 1 LIGAND-1 (PDL-1) IN THYMIC NEOPLASMS West , Heather A. Wakelee Stanford University School Of Medicine, Department Of Medicine, 1 1 2 1 2 Daniel Carvajal , Kurt Schalper , Frank Detterbeck , David Rimm , Division Of Oncology, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

5th International Thymic Malignancy Interest Group Annual Meeting

Journal of Thoracic Oncology , Volume 9 – Sep 1, 2014

Loading next page...
 
/lp/wolters-kluwer-health/5th-international-thymic-malignancy-interest-group-annual-meeting-kUoZiSWLre

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

ITMIG 2014 Abstracts Journal of Thoracic Oncology • Volume 9, Number 10, Supplement 4, September 2014 clinical data. All TETs expressed PD-L1 in our TET TMA. Though benign thymus also stained for PD-L1, TETs stained more intensely ORAL ABSTRACT SESSION 1: for PD-L1. PD-L1 expression is a potential biomarker for benefit to BIOLOGY OF THYMIC MALIGNANCIES anti-PD1/PD-L1 therapies. Our findings lend support to a clinical September 5, 2014 11:45-12:45 trial targeting PD1/PD-L1 in this rare tumor type. Disclosure: No significant relationships. ORAL ABSTRACT SESSION 1: BIOLOGY OF THYMIC MALIGNANCIES Keyword: PD-L1, PD-1, thymoma September 5, 2014 11:45-12:45 O1.01 ORAL ABSTRACT SESSION 1: BIOLOGY OF THYMIC MALIGNANCIES September 5, 2014 11:45-12:45 PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EX- PRESSION IN A THYMOMA TISSUE MICROARRAY (TMA) O1.02 1 2 Sukhmani Kaur Padda , Jonathan W. Riess , Erich Jurgen 3 4 1 1 QUANTITATIVE MEASUREMENT OF PROGRAMMED DEATH Schwartz , Lu Tian , Holbrook Edwin Kohrt , Joel W. Neal , Robert 3 1 LIGAND-1 (PDL-1) IN THYMIC NEOPLASMS West , Heather A. Wakelee Stanford University School Of Medicine, Department Of Medicine, 1 1 2 1 2 Daniel Carvajal , Kurt Schalper , Frank Detterbeck , David Rimm , Division Of Oncology,

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2014

There are no references for this article.